<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712177</url>
  </required_header>
  <id_info>
    <org_study_id>1224</org_study_id>
    <nct_id>NCT02712177</nct_id>
  </id_info>
  <brief_title>Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization</brief_title>
  <official_title>Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Immunization Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bexsero™ is a four component serogroup B meningococcal vaccine (4CMenB) licensed in Europe,
      Canada, and Australia in 2014. Prelicensure studies and post marketing surveillance data
      showed that 4CMenB has a high reactogenicity especially when coadministered with other infant
      routine vaccines [1-2]. While this suggests that coadministration causes an interaction
      resulting in a greater risk of adverse events following Immunization (AEFI) only the AEFI
      after the 4CMenB dose and not those occurring after routine vaccine immunizations were
      reported, underestimating the total risk associated with immunization at separate visits. For
      financial and practical reasons, coadministration of infant vaccines is preferred to separate
      visits. Separate visits may however be preferred if the sum of the AEFI risk at each visit is
      significantly smaller than the risk with coadministration and/or if the AEFI has a lesser
      severity. The purpose of this study is to recalculate the risk of occurrence and severity of
      AEFI with the coadministration of Bexsero™ and routine vaccines compared to separate
      injections to assess the interaction occurring with co-administration. Investigators will
      also estimate the risk of recurrence of AEFI at subsequent immunizations with the 4CMenB and
      assess if this risk varies with separate or coadministration with routine vaccines. To
      achieve these purposes, investigators will perform a secondary analysis of the data of three
      randomized controlled trials (clinicaltrials.gov identifiers: NCT00657709, NCT00847145 and
      NCT00721396) that evaluated 5025 children aged 2 to 14 months of whom 4535 were randomized to
      receive 3 to 4 doses of 4CMenB concomitantly or alternatively with routine vaccinations
      (DTaP-IPV-HepB/Hib [Infanrix Hexa™], PCV7 [Prevenar™] or MMRV [Priorix-Tetra™]) [1,2].
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fever</measure>
    <time_frame>AT RISK INTERVAL 4CMenB and inactivated routine vaccines (InRV) : Onset 24 hours following immunization (post-Imm). MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm</time_frame>
    <description>Temperature ≥ 38°C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic reactions other than fever</measure>
    <time_frame>AT RISK INTERVAL 4CMenB and InRV : Onset 24 hours post-Imm. MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm</time_frame>
    <description>systemic signs/symptoms (e.g. change in eating habits, sleepiness, unusual crying, vomiting, diarrhea, irritability…) without signs of localized infection (respiratory, urinary, etc...).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fever or systemic reactions other than fever</measure>
    <time_frame>AT RISK INTERVAL 4CMenB and InRV : Onset 24 hours post-Imm. MMRV: Onset day 5 to day 13 post-Imm.CONTROL INTERVAL 4CMenB and InRV : Onset day 4 to 7post-Imm . MMRV: Onset day 0 to 4 post-Imm</time_frame>
    <description>all systemic signs/symptoms including fever (Temperature ≥ 38°C)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site reactions</measure>
    <time_frame>AT RISK INTERVAL all injection site reactions regardless of their delay of onset. Baseline (CONTROL) risk null.</time_frame>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Actual">4535</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>Coadministration B_RV246</arm_group_label>
    <description>Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coadministration B_RV234</arm_group_label>
    <description>Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coadministration B_MMRV12</arm_group_label>
    <description>Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Separate administration B246_RV357</arm_group_label>
    <description>Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Separate administration B12_MMRV13</arm_group_label>
    <description>Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV only RV234</arm_group_label>
    <description>Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV only RV246</arm_group_label>
    <description>Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4CMenb</intervention_name>
    <arm_group_label>Coadministration B_RV246</arm_group_label>
    <arm_group_label>Coadministration B_RV234</arm_group_label>
    <arm_group_label>Coadministration B_MMRV12</arm_group_label>
    <arm_group_label>Separate administration B246_RV357</arm_group_label>
    <arm_group_label>Separate administration B12_MMRV13</arm_group_label>
    <other_name>Bexsero</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB</intervention_name>
    <arm_group_label>Coadministration B_RV246</arm_group_label>
    <arm_group_label>Coadministration B_RV234</arm_group_label>
    <arm_group_label>Coadministration B_MMRV12</arm_group_label>
    <arm_group_label>Separate administration B246_RV357</arm_group_label>
    <arm_group_label>Separate administration B12_MMRV13</arm_group_label>
    <arm_group_label>RV only RV234</arm_group_label>
    <arm_group_label>RV only RV246</arm_group_label>
    <other_name>Infanrix Hexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conjugated pneumococcal vaccine</intervention_name>
    <arm_group_label>Coadministration B_RV246</arm_group_label>
    <arm_group_label>Coadministration B_RV234</arm_group_label>
    <arm_group_label>Coadministration B_MMRV12</arm_group_label>
    <arm_group_label>Separate administration B246_RV357</arm_group_label>
    <arm_group_label>Separate administration B12_MMRV13</arm_group_label>
    <arm_group_label>RV only RV234</arm_group_label>
    <arm_group_label>RV only RV246</arm_group_label>
    <other_name>Prevenar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MMRV</intervention_name>
    <arm_group_label>Coadministration B_MMRV12</arm_group_label>
    <arm_group_label>Separate administration B12_MMRV13</arm_group_label>
    <other_name>Priorix Tetra</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy children aged 2 to 14 months selected to participate in clinical trials assessing
        the safety and immunogenicity of 4 component meningococcal serogroup B vaccine (4CMenB) in
        Austria, Belgium, Czech Republic, Finland, Germany, Italy, Spain, United Kingdom.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month old infants (55-89 days, inclusive), who were born after full term
             pregnancy with an estimated gestational age ≥ 37 weeks

          -  Parent/legal guardian has given written informed consent after the nature of the study
             has been explained.

        Main exclusion Criteria :

          -  History of any meningococcal B or C vaccine administration; prior vaccination with
             routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae
             type b (Hib), and Pneumococcal antigens);

          -  Previous ascertained or suspected disease caused by N. meningitidis; History of severe
             allergic reaction after previous vaccinations or hypersensitivity to any vaccine
             component;

          -  Significant acute or chronic infection within the previous 7 days or axillary
             temperature major or equal to38 degrees within the previous day;

          -  Antibiotics within 6 days prior to enrollment;

          -  Any serious chronic or progressive disease;

          -  Known or suspected impairment or alteration of the immune system;

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaston De Serres, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec</affiliation>
  </overall_official>
  <link>
    <url>http://www.inspq.qc.ca/pdf/publications/1885_Vaccin_Menincogoque_SerogroupeB.pdf</url>
    <description>Rapport intérimaire de surveillance de la sécurité de la première dose du vaccin contre le méningocoque de sérogroupe B au Saguenay-Lac-Saint-Jean</description>
  </link>
  <reference>
    <citation>Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.</citation>
    <PMID>22318278</PMID>
  </reference>
  <reference>
    <citation>Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013 Mar 9;381(9869):825-35. Erratum in: Lancet. 2013 Mar 9;381(9869):804.</citation>
    <PMID>23324563</PMID>
  </reference>
  <reference>
    <citation>Baker MA, Lieu TA, Li L, Hua W, Qiang Y, Kawai AT, Fireman BH, Martin DB, Nguyen MD. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. Am J Epidemiol. 2015 Apr 15;181(8):608-18. doi: 10.1093/aje/kwu322. Epub 2015 Mar 13.</citation>
    <PMID>25769306</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Gaston De Serres</investigator_full_name>
    <investigator_title>Researcher, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>vaccine safety</keyword>
  <keyword>interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

